PARIS (Reuters) - French biotechnology firm Nicox NCOX said on Monday U.S. partner Pfizer PFE had decided not to launch Phase III studies in Asia of an experimental treatment of glaucoma and ocular hypertension. "Nicox and Pfizer are currently in discussions regarding ...
August 25, 2008. Sophia Antipolis,France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the results of adose-ranging phase 2 study conducted with PF‑03187207 in Japanesepatients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitricoxide-donating prostaglandin analog. The study was designed to compare thesafety and efficacy of...
July 28, 2008. Sophia Antipolis,France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today reported its financial results forthe six months ended June 30, 2008. Key highlights for the first six months of 2008: - Completion of patient enrollment in the third naproxcinod pivotal phase 3study (303) - Post hoc...
SOPHIA ANTIPOLIS, France, July 28 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today reported its financial results for the six months ended June 30, 2008. Key highlights for the first six months of 2008: - Completion of patient enrollment in the third naproxcinod ...
SOPHIA ANTIPOLIS, France, July 24 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the top-line results from the 52-week open label safety extension that was conducted following the completion of the 301 phase 3 study for naproxcinod. The results revealed no unexpected safety findings and efficacy was maintained...
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. World Ophthalmic Pharmaceutical Drugs Market http://www.reportlinker.com/p090570/World-Ophthalmic-Pharmaceutical-Drugs-Market.html This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ Million. The major therapeutic categories analyzed are...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/0d0629/forecast_insight) has announced the addition of the "Forecast Insight: Osteoarthritis" report to their offering. Introduction With several recent non-approvable decisions in the osteoarthritis market since 2006, We have updated its forecast to account for the effect on...
SOPHIA ANTIPOLIS, France, June 13 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced an additional analysis of the blood pressure data from the 301 phase 3 study, showing a statistically significant difference between naproxcinod and naproxen in terms of the mean change from baseline in...
www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced an additional analysis ofthe blood pressure data from the 301 phase 3 study, showing a statisticallysignificant difference between naproxcinod and naproxen in terms of themean change from baseline in systolic and diastolic blood pressure at week13 (p <...
May 28, 2008. Sophia Antipolis,France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the completion of patientenrollment in the third pivotal phase 3 clinical trial for naproxcinod, inpatients with osteoarthritis of the hip (the 303 study). 810 patients havebeen randomized in 120 clinical centers in North America and...
May 27th, 2008. Sophia Antipolis,France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced that Damian Marron,Executive Vice President of Corporate Development, will be leaving thecompany on 30th May to become Chief Executive Officer of an early clinicalstage biopharmaceutical company. Damian's responsibilities will be assumedby Sanjiv Sharma, Vice President...
May 14, 2008. Sophia Antipolis,France. www.nicox.com NicOx S.A. (Eurolist: COX) today reported financial results for the firstthree months of 2008. On March 31, 2008, the Company had cash, cashequivalents and financial instruments of EUR 153.7 million, compared to EUR201.2 million on March 31, 2007. Revenues were EUR 1.4...
SOPHIA ANTIPOLIS, France, May 14 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today reported financial results for the first three months of 2008. On March 31, 2008, the Company had cash, cash equivalents and financial instruments of euro 153.7 million, compared to euro 201.2 million on March 31, 2007. ...
SOPHIA ANTIPOLIS, France, May 13 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive agents using NicOx'...
May 13, 2008. Sophia Antipolis,France. www.nicox.com NicOx S.A. (Eurolist: COX) today announced that Merck & Co., Inc. hasinitiated the first in a series of planned clinical studies, in mild tomoderate hypertensive patients, under the companies' collaborativeagreement to develop new nitric oxide-donating antihypertensive agentsusing NicOx' proprietary technology. Three drug...
www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S.phase 2 study, conducted by its partner Pfizer Inc, which compared thesafety and efficacy of various doses of PF-03187207 to Xalatan®latanoprost 0.005% in patients with primary open-angle glaucoma andocular hypertension. The higher doses of PF-03187207 demonstrated aclinically...
SOPHIA ANTIPOLIS, France, May 6 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to XalatanR latanoprost 0.005% in patients with primary open-angle glaucoma...
www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced it has signed anagreement with the fine chemical company Archimica, for thecommercial manufacturing and supply of naproxcinod drug substance(or active pharmaceutical ingredient, API). Naproxcinod is NicOx'lead investigational product and the first compound in the COX-Inhibiting Nitric Oxide-Donating CINOD class of anti-inflammatory...
www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the initiation of two largeclinical pharmacology studies in the United States, which will assess the bloodpressure profile of naproxcinod in comparison to ibuprofen and naproxen, usingthe Ambulatory Blood Pressure Monitoring ABPM technique. These separatestudies, 12 and 16 weeks in duration, will...
www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced its financial results for 2007and provided an overview of its activities during the year. NicOx also announcedtoday the initiation of two large Ambulatory Blood Pressure Monitoring ABPMstudies for naproxcinod see separate press release. Key highlights 2007: - Initiation of the two...
Articles 2008-03-03
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
Choose up to 5" more legroom with Economy Plus. Starting at $14.
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
